Votrient — Class III drug recall D-0149-2024
Completed recall by Siegfried Barbera, SL, reported 2023-12-20, distributed nationwide. Failed Dissolution Specifications
| Recall number | D-0149-2024 |
|---|---|
| Product type | Drug |
| Classification | Class III |
| Status | Completed |
| Voluntary or mandated | Voluntary |
| Recalling firm | Siegfried Barbera, SL, Barbera Del Valles, N/A, Spain |
| Recall initiated | 2023-11-20 |
| Classified | 2023-12-13 |
| Reported by FDA | 2023-12-20 |
| Distributed | Nationwide (US) |
| Quantity | 2,016 |
| Reason classes | specification failure |
| NDC | 00078-1077, 00078-1077-66 |
| Lot numbers | ME2713, MF8286, ML1860 |
| Expiration dates | 2025-02, 2025-04 |
Product
Votrient (pazopanib) 200 mg tablets, 120-count bottle, Rx Only, Manufactured by: Siegried Barbera, S.L., Barbera del Valles, Spain, Distributed by: Novartis Pharmaceuticals Corp., East Hanover, N.J. 07936, NDC 0078-1077-66
Reason for recall
Failed Dissolution Specifications
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0149-2024. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.